Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

Kim, Geoffrey, McKee, Amy E., Ning, Yang-Min, Hazarika, Maitreyee, Theoret, Marc, Johnson, John R., Xu, Qiang Casey, Tang, Shenghui, Sridhara, Rajeshwari, Jiang, Xiaoping, He, Kun, Roscoe, Donna, McGuinn, W. David, Helms, Whitney S., Russell, Anne Marie, Miksinski, Sarah Pope, Zirkelbach, Jeanne Fourie, Earp, Justin, Liu, Qi, Ibrahim, Amna, Justice, Robert, Pazdur, Richard · 2014 · Clinical Cancer Research

Abstract

On August 17, 2011, the U.S. Food and Drug Administration (FDA) approved vemurafenib tablets (Zelboraf, Hoffmann-LaRoche Inc.) for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test. The cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.) was approved concurrently. An international, multicenter, randomized, open-label trial in 675 previously untreated patients with BRAFV600E mutation–positive unresectable or metastatic melanoma allocated 337 patients to receive vemurafenib, 960 mg orally twice daily, and 338 patients to receive dacarbazine, 1,000 mg/m2 intravenously every 3 weeks. Overall survival was significantly improved in patients receiving vemurafenib [HR, 0.44; 95% confidence interval (CI), 0.33–0.59; P < 0.0001]. Progression-free survival was also significantly improved in patients receiving vemurafenib (HR, 0.26; 95% CI, 0.20–0.33; P < 0.0001). Overall response rates were 48.4% and 5.5% in the vemurafenib and dacarbazine arms, respectively. The most common adverse reactions (≥30%) in patients treated with vemurafenib were arthralgia, rash, alopecia, fatigue, photosensitivity reaction, and nausea. Cutaneous squamous cell carcinomas or keratoacanthomas were detected in approximately 24% of patients treated with vemurafenib. Other adverse reactions included hypersensitivity, Stevens–Johnson syndrome, toxic epidermal necrolysis, uveitis, QT prolongation, and liver enzyme laboratory abnormalities. Clin Cancer Res; 20(19); 4994–5000. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0776

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 212

Metadata

Authors
Kim, G., McKee, A. E., Ning, Y.-M., Hazarika, M., Theoret, M., Johnson, J. R., Xu, Q. C., Tang, S., Sridhara, R., Jiang, X., He, K., Roscoe, D., McGuinn, W. D., Helms, W. S., Russell, A. M., Miksinski, S. P., Zirkelbach, J. F., Earp, J., Liu, Q., Ibrahim, A., Justice, R., & Pazdur, R.
Venue
Clinical Cancer Research
Published
2014-09-30
Volume
20
Issue
19
Pages
4994-5000
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2112276477
Cited by
212
References
6
FWCI
5.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0776
The paper
Kim, G., McKee, A. E., Ning, Y.-M., Hazarika, M., Theoret, M., Johnson, J. R., Xu, Q. C., Tang, S., Sridhara, R., Jiang, X., He, K., Roscoe, D., McGuinn, W. D., Helms, W. S., Russell, A. M., Miksinski, S. P., Zirkelbach, J. F., Earp, J., Liu, Q., . . . Pazdur, R. (2014). FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0776

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.